Pediatric Bladder Treatment Global Market Report 2024

The global pediatric bladder treatment market has grown strongly in recent years. It will grow from $3.36 billion in 2023 to $3.54 billion in 2024 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to prevalence of pediatric bladder conditions, growing awareness of pediatric bladder conditions, increasing access to healthcare for children, rising disposable incomes.

The global pediatric bladder treatment market is expected to see steady growth in the next few years. It will grow to $4.23 billion in 2028 at a compound annual growth rate (CAGR) of 4.5%. The growth in the forecast period can be attributed to aging population, rising prevalence of chronic diseases in children, increasing access to healthcare, demand for personalized medicine in the treatment. Major trends in the forecast period include adoption of new and innovative pediatric bladder treatments, digital health technologies, early intervention and prevention, non-invasive treatments.

The rising prevalence of pediatric bladder disorders is poised to fuel the expansion of the pediatric bladder treatment market in the foreseeable future. Pediatric bladder disorders encompass a range of medical conditions that disrupt the normal functionality of the urinary bladder in children. These conditions, often associated with ailments like spina bifida and neurological disorders, result in urinary complications in children, necessitating effective treatment approaches. For example, a study involving 1,065 pediatric patients with neurogenic bladder (NGB, a type of pediatric bladder disorder), conducted in March 2023 and published by the Multidisciplinary Digital Publishing Institute (MDPI), revealed that 38.9% of these patients had spina bifida. Lower urinary tract infections were a prevalent complication (18.1%), especially among patients with open spina bifida (54.1%). Over a 12-month follow-up, common complications included recurrent lower urinary tract infections (18.1%), urinary incontinence (8.0%), and hydronephrosis (5.6%), with 7.9% of patients experiencing four or more recurring lower urinary tract infections. Consequently, the surge in pediatric bladder disorders is a key driver of growth in the pediatric bladder treatment market.

The growing acceptance of minimally invasive procedures is poised to revolutionize the pediatric bladder treatment market's growth in the coming years. Minimally invasive procedures encompass medical and surgical methods characterized by the use of small incisions, delicate instruments, and advanced imaging technology. The rising application of minimally invasive interventions in pediatric bladder treatment offers several advantages, including swifter recovery, reduced discomfort, and enhanced safety. These benefits position minimally invasive techniques as more effective and appropriate options for addressing pediatric bladder issues. For example, as reported by Intuitive Surgical Inc., a US-based manufacturer of robotic systems, the year 2022 witnessed around 1,875,000 surgical procedures carried out using Vinci Surgical Systems, signifying an impressive 18% surge in comparison to the approximately 1,594,000 surgical procedures conducted with Vinci Surgical Systems in 2021. As such, the increasing adoption of minimally invasive procedures drives the growth of the pediatric bladder treatment market.

The absence of physical restraint-free treatment poses a significant challenge and has the potential to restrict the market's growth during the forecast period. The utilization of physical restraints during treatment stands as a substantial hindrance in the pediatric bladder treatment market, primarily due to the physical and emotional distress it can inflict upon patients and their caregivers. It is associated with negative perceptions of healthcare providers, the treatment process, concerns about the lack of consent, and safety issues. For example, as per a qualitative study published in the Journal of Child Health Care in 2021, the absence of physical restraint is sometimes regarded as a limitation in providing care or treatment for pediatric patients. This can create a notable barrier to effective treatment, causing physical and emotional distress for the patient and their caregivers. Consequently, the lack of physical restraint-free treatment hampers the growth of the pediatric bladder treatment market.

The prominent companies operating in the pediatric bladder treatment market are actively engaged in the development of precision therapies aimed at addressing specific medical conditions within the pediatric population. These therapies offer tailored solutions to accommodate the unique challenges and medical requirements of pediatric patients with bladder disorders. Targeted pediatric bladder treatment therapies are characterized by their specialized and precise approach to effectively cater to the needs of children. For example, in March 2021, Astellas Pharma Inc., a Japan-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron extended-release oral suspension). These therapies are designed to treat neurogenic detrusor overactivity (NDO) in pediatric patients aged three years and older. NDO is a bladder dysfunction resulting from nerve damage, leading to involuntary bladder contractions and causing symptoms like frequent urination, urgency to urinate, and urinary incontinence. Myrbetriq tablets (Mirabegron extended-release tablets) are currently available in the U.S. market.

In July 2021, UroMedical Corporation, a medical device manufacturer based in the United States, completed the acquisition of Micron Medical Corporation, and the terms of the deal were not disclosed. This strategic acquisition allowed UroMedical Corporation to bolster its assets in the field of urology, thereby establishing itself as a prominent provider of urology-focused products. The move involved ongoing essential clinical trials, bolstered its market presence, and streamlined the regulatory approval process for innovative neurostimulation solutions aimed at enhancing the management of urological conditions, with a particular emphasis on pediatric neurogenic bladder. Micron Medical Corporation, also based in the United States, is a biopharmaceutical company renowned for its expertise in pediatric neurogenic bladder management.

Major players in the pediatric bladder treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd, AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca Plc, Takeda Pharmaceutical Company Limited, Medtronic Plc, Teva Pharmaceutical Industries Ltd., Boston Scientific Corporation, Mylan N.V., Astellas Pharma Inc, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cook Medical Inc., Ipsen Pharma, Aurobindo Pharma Ltd, Endo International plc, Coloplast AIS, Endo International plc, Apotex Inc., Amneal Pharmaceuticals LLC., Orion Corporation, Taro Pharmaceuticals, Laborie Medical Technologies Corp., Salix Pharmaceuticals, TherapeuticsMD Inc., UroGen Pharma, Palette Life Sciences, Sumitovant Biopharma.

North America was the largest region in the pediatric bladder treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pediatric bladder treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pediatric bladder treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of pediatric bladder treatment for these disorders consist of diurnal incontinence, enuresis, and other related conditions. Diurnal incontinence pertains to the involuntary release of urine during daylight hours, when an individual should typically have control over their bladder. Treatment for diurnal incontinence in children often includes behavioral and lifestyle adjustments, such as educating the child to recognize and respond to the sensation of a full bladder, encouraging regular bathroom breaks, and addressing any issues related to constipation. These conditions are also managed through urotherapy, medication, surgical reconstruction, and other treatment methods, administered orally, parenterally, or through alternative routes. The treatment products are distributed through various channels, including hospital pharmacies, online pharmacies, and retail pharmacies, and cater to end users such as hospitals, homecare services, specialty clinics, and more.

This report provides pediatric bladder treatment market statistics, including pediatric bladder treatment industry global market size, regional shares, competitors with a pediatric bladder treatment market share, detailed pediatric bladder treatment market segments, market trends and opportunities and any further data you may need to thrive in the pediatric bladder treatment industry. This pediatric bladder treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pediatric bladder treatment market consists of revenues earned by entities by providing medical consultations, nutritional counseling, catheterization and therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The pediatric bladder treatment market also includes sales of ultrasound devices, cystoscopes, antibiotics, urinary catheters, incontinence products and surgical instruments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.